SPHK1/S1P signaling has been linked to cancer progression and metastasis,[3] as it modulates many key oncogenic events, such as proliferation, migration, invasion, adhesion, angiogenesis, and apoptosis.[4] Consistent with these observations, we found elevated S1P levels in high‐grade serous ovarian cancer patients’ plasma and high SPHK1 enzyme expression in tissue samples. This evidence concerns the gene SPHK1 and ovarian serous adenocarcinoma.